Showing 3 posts of 3 posts found.


Teva’s Austedo fails in two paediatric Tourette’s syndrome trials

February 21, 2020
Medical Communications, Research and Development Austedo, Teva, pharma, tourette's

Israeli firm Teva has shared disappointing results for its vesicular monoamine transporter 2 (VMAT2) Austedo (deutetrabenazine) after it failed to …

Lundbeck acquire Abide Therapeutics in deal worth $400 million

May 7, 2019
Manufacturing and Production, Sales and Marketing Abide Therapeutics, Lundbeck, endocannabinoid system, neuropathic pain, tourette's

Danish firm Lundbeck has agreed to acquire San Diego-based biotech Abide Therapeutics as part of a deal worth $400 million. …


Neurocrine’s Ingrezza flops in Tourette’s for second time

May 25, 2017
Research and Development, Sales and Marketing Neurocrine Biosciences, tourette's

Neurocrine’s Tourette’s therapy Ingrezza (valbenazine) has been hit with yet another setback, flopping in a Phase 2 trial of paediatric …

Latest content